Sotera Health (NASDAQ:SHC) Upgraded at The Goldman Sachs Group

Sotera Health (NASDAQ:SHC - Get Free Report) was upgraded by analysts at The Goldman Sachs Group from a "neutral" rating to a "buy" rating in a research note issued on Monday, Marketbeat reports. The brokerage presently has a $17.00 price objective on the stock, up from their previous price objective of $14.00. The Goldman Sachs Group's price target would indicate a potential upside of 28.50% from the stock's current price.

Other research analysts also recently issued research reports about the stock. Piper Sandler decreased their price objective on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Barclays reduced their price target on Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Sotera Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.80.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded up $0.08 during mid-day trading on Monday, hitting $13.23. The stock had a trading volume of 1,011,205 shares, compared to its average volume of 1,209,826. The firm has a market cap of $3.76 billion, a PE ratio of 52.92 and a beta of 1.88. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a 50 day moving average of $11.39 and a two-hundred day moving average of $12.98. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.13 EPS. Research analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Sotera Health

A number of hedge funds have recently made changes to their positions in SHC. Xponance Inc. increased its position in shares of Sotera Health by 6.0% during the fourth quarter. Xponance Inc. now owns 17,495 shares of the company's stock worth $239,000 after purchasing an additional 989 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Sotera Health by 0.3% during the first quarter. Principal Financial Group Inc. now owns 352,388 shares of the company's stock worth $4,109,000 after buying an additional 1,037 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sotera Health by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company's stock worth $711,000 after buying an additional 1,047 shares in the last quarter. New York State Teachers Retirement System raised its position in shares of Sotera Health by 1.9% in the first quarter. New York State Teachers Retirement System now owns 59,273 shares of the company's stock valued at $691,000 after buying an additional 1,100 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Sotera Health by 37.5% in the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock worth $56,000 after buying an additional 1,121 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.